Streetwise Regenerative Medicine Articles


2018 Biotech Watchlist: 'No One Space Is Going to Dominate'

  ()
Michael King of JMP Securities provides a comprehensive round-up of companies he has selected for the 2018 Biotech Watchlist—companies in immuno-oncology, gene editing, and other indications that he believes offer promising opportunities for patients and investors. read more >

'Exciting' Collaborations Possible for Biotech's 'Flexible' Platform

Research Report
  ()
Zacks Small-Cap Research's John Vandermosten discussed the potential for this immunotherapy firm's RNAi compounds in oncology. read more >

A New Breed of Regenerative Therapy Companies Taking Hold

Contributed Opinion
  ()
A regenerative therapy company with expertise in both cell therapy development and manufacturing, and a potential treatment for diabetes, differentiates this company, says Hunter Diamond, CFA, CEO of Diamond Equity Research. read more >

Biotech Reports Positive Topline Data; Biologics License Application in Progress

Research Report
  ()
Ram Selvaraju, an analyst with H.C. Wainwright & Co., reviewed the recent clinical trial results released by this developer of cell therapies targeting oncology and orphan indications. read more >

Coverage Initiated on Gene Therapy Company

Research Report
  ()
Analyst David Nierengarten with Wedbush explained the rationale for adding this biotech to his coverage universe. read more >

Biotech Releases Initial Zika Vaccine Trial Results; Advances Combo Trials

  ()
With multiple candidates in the pipeline advancing through clinical trials, Ram Selvaraju, an analyst with H.C. Wainwright & Co., provided insight into developments at a biotech addressing Zika virus, advanced bladder cancer and cervical dysplasia. read more >

Japan Is Fertile Ground for Biotech Deals

  ()
Japan and the United States are hotspots for companies that are looking to license-out exciting regenerative medicine technology, says Colin Lee Novick, managing director of CJ PARTNERS. In this interview with The Life Sciences Report, Novick discusses a regenerative medicine company pursuing partnerships in Japan for its cell therapies to treat chronic tendinosis, damaged or aged skin, and pattern baldness. read more >
Management Q&A: View from the Top

Biotech with Transformative RNAi Delivery System Set for Multiple Catalysts by Year-End

Managment Q&A: View from the Top
  ()
With data from multiple studies due out this quarter, this biotech's RNA interference delivery platform has the potential to transform treatments for indications from cancer to ophthalmology, says Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals, Dr. Gerrit Dispersyn, RXi's Chief Development Officer, and Dr. Karen Bulock, Vice President of Research at RXi. read more >

Small-Cap Biotech Benefits from First FDA Approval of CAR-T Therapy

Research Report
  ()
The first approval of a cell therapy for treatment of pediatric blood cancer prompted H. C. Wainwright to increase its price target for a UK-based biotech manufacturing one of the therapy's components. read more >

With Acquisition of Kite Pharma, Gilead Becomes a 'Major Player' in CAR-T Arena

Research Report
  ()
Jason Kolbert, analyst with Maxim Group, assesses the billion-dollar transaction that would bring Kite Pharma and the earning potential of its cell therapy programs under the larger biotech's umbrella. read more >

Analyst Says Cell Therapy Company's Move Decreases Risk

Research Report
  ()
A regenerative medicine company has signed on to the ThawSTAR Early Adopter Program, a move analyst Douglas Loe of Echelon Wealth Partners terms "positive logistically" to development risk. read more >

'Keep a Close Eye On' This Regenerative Medicine Firm

Research Report
  ()
In an update on this company's clinical cell therapy programs targeting blood cancers and osteoarthritis in the knee, Gabrielle Zhou of Maxim Group describes progress that sets the stage for "value inflection." read more >

2017 Small-Cap Biotech Watchlist Update: Up 21% at the End of Q2/17

  ()
If an investor had purchased an equal dollar amount of each company on The Life Sciences Report's 2017 Small-Cap Biotech Watchlist at the beginning of the year, that portfolio would show a gain of about 21% as of July. This is primarily due to the performance of a handful of companies that have been moving their assets farther down the development pipeline, according to the analysts who follow them. read more >

RXi Pharmaceuticals Expands Collaboration with Norwegian Cancer Firm; Gears Up for 2017 Milestones

Source:   ()
The potential of RXi Pharmaceuticals' sd-rxRNA technology in the development of cancer immunotherapies has resulted in an extension of its research collaboration with Oslo-based PCI Biotech and captured the attention of two analysts. read more >

Mesoblast Heart Failure Trial Delivers Positive Interim Results

Source:   ()
Mesoblast Ltd., an Australia-based regenerative medicine company currently in a Phase 3 clinical trial in chronic heart failure, has received successful interim data, which prompted the Maxim Group to comment favorably on the study's design and progress. read more >

2017 Small-Cap Biotech Watchlist Update: Holding Steady in a Volatile Market

Source:   ()
The Small-Cap Biotech Watchlist, composed of 20 companies targeting a range of indications including blood cancers and solid tumors, irritable bowel disease and orphan diseases, has posted a modest gain since the first of the year. read more >

String of Positive Trial Results Boosts RepliCel's Profile

Source:   ()
Positive results from RepliCel's Phase 1 trial for the treatment of aging and sun-damaged skin follow the release in the past few weeks of positive data from trials for chronic tendon problems and for hair loss. read more >

RXi Pharmaceuticals Receives Japanese Patent for RNAi Platform

Source:   ()
With the granting of a new patent in Japan for its lead compound, RXI-109, RXI Pharmaceuticals has strengthened its reach in Asian markets and enhanced the protections surrounding its proprietary RNAi platform. read more >

RepliCel's Phase 1 Trial for Hair Loss Completed Successfully

Source:   ()
RepliCel's successful conclusion of its Phase 1 trial for hair loss sets it up for the next steps in the drug's development. read more >

Regeneus Hits the Fast Track with Major Japanese Partnership

Source: The Life Sciences Report  (02/08/2017)
Regeneus Hits the Fast Track with Major Japanese Partnership
Regeneus, an Australian regenerative medicine company, has entered into a collaboration with a major Japanese firm to manufacture its stem cell therapy Progenza, a move that may accelerate approval and that has a pair of analysts optimistic about the company's future. read more >

Companies Flocking to Japan for Biotech Deals

Source: Colin Lee Novick for The Life Sciences Report  (02/01/2017)
Companies Flocking to Japan for Biotech Deals
For the last two years, Japan has been at the forefront of accelerated approval for regenerative medicine products and has seen lots of licensing and contract manufacturing deals and M&A activity. Tokyo-based Colin Lee Novick, managing director of CJ PARTNERS, surveys the landscape, discussing recent tie-ups, the effects of the recently passed 21st Century Cures Act in the U.S., and what may lie ahead. read more >

2017 Small-Cap Biotech Watchlist: Takeaways for Investors

Source:   ()
Why should investors keep an eye on these twenty small-cap biotechs in 2017? The analysts who made the selections for The Life Sciences Report's 2017 Small-Cap Biotech Watchlist laid out their rationales at the Watchlist's launch at the Biotech Showcase in San Francisco on Jan. 11. read more >

Time to Go Long on BrainStorm Cell Therapeutics?

Contributed Opinion
Source: Jason Napodano CFA of BioNap Inc. for The Life Sciences Report  (01/16/2017)
Time to Go Long on BrainStorm Cell Therapeutics?
Jason Napodano of BioNap Consulting takes an in-depth look at BrainStorm Cell Therapeutics, including the science, the Phase 2 data and the potential valuation of the company developing adult stem cell-based therapies for neurodegenerative diseases. read more >

19 Companies Selected for the 2017 Small-Cap Biotech Watchlist

Source:   ()
Now in its fifth year, the 2017 Life Sciences Report Biotech Watchlist includes nineteen small-cap biotech companies selected by top analysts in the field, and will be presented at the Biotech Showcase in San Francisco in January. read more >

VistaGen Licenses Stem Cell Technology to New Firm Backed by Big Pharma

Source: The Life Sciences Report  (12/21/2016)
VistaGen Licenses Stem Cell Technology to New Firm Backed by Big Pharma
VistaGen Therapeutics has granted an exclusive sublicense for its stem cell technologies to BlueRock Therapeutics, a new biotech backed by pharma heavyweight Bayer AG and venture capital firm Versant Ventures of San Francisco. read more >
Showing Results: 1 to 25 of 55 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free

A valid email address is required to subscribe

More Experts